A line of of Chromatin Immunoprecipitation (ChIP)-validated antibodies was recently launched by Chromatrap. The new antibodies build on the company’s work in the solid-state ChIP market, which underpins modern epigenetic research. The addition of ChIP-validated antibodies enhances the high-performance application solutions that Chromatrap can provide researchers.
“The use of high-quality and specific ChIP-validated antibodies is essential for the success of a ChIP assay,” said Dr Amy Beynon, Chromatrap product development manager. “The antibody must recognize and bind to native protein that is bound to DNA. Antibodies from other applications do not always work well in ChIP. That is why our team has thoroughly investigated the top ten most referenced antibodies in recent epigenetic research papers.”
A range of ChIP kits for qPCR or sequencing includes the following nine antibodies, which are available in the company’s validated antibody program: H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a. The range will be expanded as the company continues to identify, source and validate antibodies for ChIP experimental use. Most of the major epigenetic marks are expected to be validated over the next 12 months. Chromatrap, part of Porvair Sciences
Print this page